Benzinga | Aug 6, 2020 04:47PM EDT

Regenxbio Q2 EPS $(0.91) Beats $(0.94) Estimate, Sales $16.57M Miss $22.07M Estimate

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(0.91) per share which beat the analyst consensus estimate of $(0.94) by 3.19 percent. This is a 2175 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $16.57 million which missed the analyst consensus estimate of $22.07 million by 24.94 percent. This is a 110.20 percent increase over sales of $7.88 million the same period last year.